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Endosialin, also named as tumor endothelial marker 1 (TEM1) or CD248, is a poorly 
known cancer associated glycoprotein which has been found to express in different 
kinds of tumors, but not in normal tissues. There are several suggested functions for 
endosialin, but the overall function, activating mechanisms, signaling pathways and 
regulation are still mainly unknown. In this study the expression patterns of endosialin 
in human tumors was analyzed by immunohistochemistry. The aims of the study were 
to find out the suitability of two endosialin monoclonal antibodies for immunostaining 
and to compare the expression of two endosialin antibodies between human tumor spe-
cimens and normal tissues.  
 
The expression of endosialin was investigated by immunohistochemistry. Tumor spe-
cimens were processed and immunostained with two different endosialin monoclonal 
antibodies II-50/3 and VIII-16. The used immunostaining technique was indirect me-
thod. Secondary antibody was labeled with horseradish peroxidase. Staining intensity 
was investigated with light microscope and results were analyzed statistically.  
 
In this study the results suggested that both the antibodies function well, but the overall 
staining intensity was bit stronger with antibody VIII-16. Moreover it was found that 
brain, colon and skin tissues stained more intensively than pancreatic tissues or hepato-
biliary lesions. The strongest staining intensity was found in skin specimens. However 
endosialin functioned best in brain specimens where intense staining was observed in 
brain tumors and weak staining was observed in normal brain specimens. Correlation 
between staining intensity and different tumor grades was not found in this study. 
 
According to the results of this study connection between endosialin and cancer was 
observed. This study indicates that endosialin could possibly in future serve as a tool in 
development towards better cancer treatment. Whether it has potential to become a spe-
cific molecular biomarker is uncertain, because in this study specificity and other typi-
cal features of molecular biomarkers were not found. 
 
 
 
 
 
 
 
 
Key words: Tumor, immunohistochemistry, immunostaining, endosialin, TEM1, mole-
cular biomarker. 
3 
 
TIIVISTELMÄ 
 
Pirkanmaan ammattikorkeakoulu 
Laboratorioalan koulutusohjelma 
 
TUOMAALA, PAULIINA:  
Endosialiinin määritys ihmisen kasvainkudosnäytteistä immunohistokemiallisesti. 
 
Opinnäytetyö 54 s., liitteet 4 s. 
Joulukuu 2009 
 
Endosialiini, TEM1 (tumor endothelial marker 1) tai CD248, on tällä hetkellä vielä 
melko huonosti tunnettu usein syöpään liitetty glykoproteiini.  Endosialiinin on havaittu 
ilmentyvän voimakkaammin kasvainkudoksissa kuin normaaleissa kudoksissa. Sen toi-
mintaa on yritetty selvittää lukuisissa tutkimuksissa, mutta esimerkiksi aktivaatiomeka-
nismeja, solunsisäisiä signalointireittejä tai säätelyä ei tästä huolimatta tunneta vielä 
varmuudella. Tässä tutkimuksessa endosialiinin ilmentymistä tutkittiin erilaisissa ihmi-
sen kasvaimissa immunohistokemiallisesti. Tutkimuksen tavoitteina oli selvittää kahden 
monoklonaalisen endosialiinivasta-aineen soveltuvuutta immunovärjäykseen ja vertailla 
vasta-aineiden ilmentymistä ihmisen kasvainkudosten ja normaalien kudosten välillä.  
 
Endosialiinin ilmentymistä tutkittiin immunohistokemiallisesti. Kasvainkudosnäytteet 
käsiteltiin ja immunovärjättiin kahdella eri monoklonaalisella endosialiinivasta-aineella 
II-50/3 ja VIII-16. Käytetty immunovärjäystekniikka oli epäsuora menetelmä. Sekun-
daarivasta-aine oli leimattu piparjuuriperoksidaasilla. Immunovärjäyksen intensiteettiä 
tutkittiin valomikroskoopilla ja saatuja tuloksia tarkasteltiin tilastollisella analyysillä. 
 
Saatujen tutkimustulosten perusteella kumpikin immunovärjäykseen käytetyistä mono-
klonaalisista endosialiinivasta-aineista toimi hyvin. Kaiken kaikkiaan värjäytyminen oli 
hieman voimakkaampaa vasta-aineella VIII-16. Lisäksi havaittiin, että aivo-, pak-
susuoli- ja ihokudos värjäytyivät voimakkaammin kuin haima- ja maksakudos. Voi-
makkain värjäytyminen oli nähtävissä ihokudoksessa. Endosialiini toimi kuitenkin par-
haiten aivokudoksessa, jossa kasvainkudoksen värjäytyminen oli selvästi voimakkaam-
paa kuin normaalin kudoksen. Tässä tutkimuksessa värjäytymisen voimakkuuden ja 
kasvaimen pahanlaatuisuusasteen välillä ei löydetty yhteyttä.   
 
Tutkimuksessa saadut tulokset viittaavat endosialiinin ja syövän yhteyteen. Endosialii-
nilla saattaa olla merkitystä syöpätutkimuksessa ja tulevaisuuden syöpälääkkeiden kehi-
tyksessä. On kuitenkin epävarmaa, onko endosialiinissa ainesta syövän molekulaarisek-
si biomarkkeriksi, koska biomarkkeireiden tyypillisiä piirteitä kuten spesifisyyttä ei täs-
sä tutkimuksessa havaittu.  
  
 
 
 
 
 
 
 
Avainsanat: Kasvain, immunohistokemia, immunovärjäys, endosialiini, TEM1, moleku-
laarinen biomarkkeri. 
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ABBREVIATIONS 
 
 
AA  Anaplastic astrocytoma, grade 3 
bp  Base pairs 
cDNA  Complementary DNA 
CD248  Endosialin 
CML  Chronic myeloid leukemia 
DA  Diffuse astrocytoma, grade 2 
DAB  3,3’-diaminobenzidine tetrahydrochloride 
ECM  Extracellular matrix 
EGF  Endothelial growth factor 
EPC  Endothelial precursor cell 
GBM  Glioblastoma multiforme, grade 4 
GIST  Gastrointestinal stromal tumor  
GS  Gliosarcoma, grade 4 
HEMA  Hematoxylin 
HER2  Human epidermal growth factor receptor 2 
HNPCC  Hereditary nonpolyposis colorectal cancer 
HRP  Horseradish peroxidase 
IFN-α  Interferon-α 
KO  Knockout 
mRNA  Messenger RNA 
MSI  Microsatellite instable 
MSS  Microsatellite stable 
PAGE  Polyacrylamide gel electrophoresis 
PSA  Prostate-specific antigen 
RT-PCR  Reverse transcriptase polymerase chain reaction 
SAGE  Serial analysis of gene expression 
SEM  Standard error of mean 
TBS-TWEEN Tris buffered saline with tween 
TEM1  Tumor endothelial marker 1, endosialin 
VEGF  Vascular endothelial growth factor 
WT  Wild-type 
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1 INTRODUCTION 
 
 
Histology is the study of the tissues (Greek words histo, tissue and logos, study) (Jun-
queira & Carneiro 2003, 1). It investigates microscopic structures and individual com-
ponents of biological material (Stevens & Lowe 2000, 1). Tissues are comprised of sev-
eral types of cells and extracellular matrix (ECM). Extracellular matrix consists of many 
kinds of molecules secreted by cells. The main functions of extracellular matrix are to 
support cells and transport nutrients to cells. (Junqueira & Carneiro 2003, 1.) 
 
Histology has been used in diagnostic medicine for long. Histological examination of 
tissue samples is an important tool for histopathologic diagnostics of diseases. Through 
histological examination it is possible to distinguish normal tissue from diseased tissue 
and to determine which kind of disease is in question. For histological analysis tissues 
are usually processed and stained before microscopy, because they are usually too thick 
and also transparent for direct microscopy. Cells or specific tissue components are re-
vealed in histological staining process. Histological staining provides examination of 
chemical nature of the tissues. (Alberts et al. 2008, 585.) 
 
Immunohistochemical staining methods have considerably developed during the past 
few decades. Immunodiagnostic methods have had an important influence especially on 
development of histopathologic diagnostics. The use of immunological stains has be-
come a routine diagnostic tool in most laboratories. (Carson 1997, 228.) Immunostain-
ing exploits specific binding between antibody and antigen. Antibodies are proteins 
produced by immune system as a defense against infection. They are made of different 
forms with different binding sites, epitopes, that recognize target molecule, antigen, 
with high specificity. The location of antigen in sample can be precisely revealed with 
use of labeled antibodies. (Alberts et al. 2008, 588.) 
 
Cancer is a genetic disease that arises as a consequence of genetic changes in DNA. 
According to American cancer society and international union against cancer there were 
12 million cancers diagnosed last year with 7 million deaths worldwide. (Aggarwal et 
al. 2009, 1083-1084.) Despite the fact that knowledge of cancer has increased, the pre-
vention and treatment is still deficient (Negm, Verma & Srivastava 2002, 288). Annual-
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ly about 20 billion dollars are spent to find proper cures for cancer (Aggarwal et al. 
2009, 1083.) 
 
Initiation of cancer involves interaction of carcinogens with DNA. This interaction leads 
to somatic mutations and further to transformation of normal cells to tumor cells. The 
initiation is usually followed by promotion, the step in which cancer cells proliferate 
and form solid tumors. (Aggarwal et al. 2009, 1083.) There are two properties characte-
ristic of cancer cells: Their reproduction differs from normal cell growth and division 
and they invade and colonize other cells’ territories. Invasiveness is vital to cancer cells, 
because this ability allows cancer cells to enter blood or lymphatic vessels and form 
metastases. (Alberts et al. 2008, 1206.) 
 
The earlier the cancer is diagnosed, the better treatment results will be achieved. At this 
moment cancer treatment has been concentrated on the early diagnosis of cancer and 
personalized medicine. (Negm et al. 2002, 288.) The early diagnosis of cancer has be-
come possible through understanding of the molecular changes that happen in cells long 
time before the actual onset of cancer. These changes are called molecular biomarkers 
and they have been learnt to detect with novel improvements in technology. Detection 
of molecular biomarkers has helped us in development of new targeted anticancer drugs 
and therapies against different types of cancers. (Srinivas, Kramer & Srivastava 2001, 
698.) 
 
Endosialin, also named as tumor endothelial marker 1 (TEM1) or CD248, is a cancer 
associated protein. Endosialin has observed to express in tumor tissues, but not in nor-
mal tissues. The expression has been found in humans as well as in mice. Endosialin 
may have potential as a therapeutic target in developing cancer therapies. That is the 
reason why it attracts researcher’s attention. (McFadyen et al. 2007, 363.) 
 
The aim of the study is to identify the expression of endosialin in human tumors by im-
munohistochemistry. The study was carried out in summer of 2009 at the Institute of 
Medical Technology, University of Tampere, in the research group of tissue biology led 
by Professor Seppo Parkkila. This study was performed under the valued supervision of 
Professor Parkkila and laboratory technician Aulikki Lehmus. 
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2 REVIEW OF THE LITERATURE 
 
 
2.1 Tumor diagnostics 
 
A tumor is formed of abnormal mass of cells that grow and proliferate out of control. 
Tumor is said to be benign as long as its cells do not become invasive. Tumor is consi-
dered a cancer only when the tumor is malignant and its cells have gained the ability to 
invade surrounding tissues. (Alberts et al. 2008, 1206.) 
Cancer is generally diagnosed when person get physical symptoms. After physical ex-
amination usually imaging studies are performed to produce pictures and to get more 
information of the tumor. Imaging studies such as x-rays, computed tomography scans, 
magnetic resonance imaging scans and positron emission tomography scans show for 
example the location and size of the tumor and whether it has spread in foreign tissues 
and formed metastases. Imaging studies have an important role in determining stage of 
the cancer. (National Cancer Institute 2004a.) 
The purpose of cancer staging systems is to produce detailed information of cancer. 
Through cancer staging extent of the cancer spread and severity can be defined. There 
are lots of staging systems for many types of cancers. (National Cancer Institute 2004a.) 
Analyzed topics in cancer staging are often location of the primary tumor, size of the 
tumor, number of tumors, whether the cancer has spread to lymph nodes, cell type and 
presence or absence of metastases. (Cancer Treatment Watch 2005.) 
According to normal cancer diagnostic pattern laboratory tests are subsequently taken to 
gain more information about the cancer. Laboratory tests may involve sampling of 
blood, urine or other fluids, but also tissue samples, or in some cases the entire tumor, 
are often removed from the cancer in a procedure called a biopsy. (National Cancer In-
stitute 2004a; Cancer Treatment Watch 2005.) These tissue specimens are usually ex-
amined under a microscope by pathologists whose reports usually contain once again 
even more precise information about the cancer. Pathologists also determine the grade 
of the cancer. (Cancer Treatment Watch 2005.) 
The tumor grade is a description of the tumor based on how abnormal the cancer cells 
look like under a microscope and how quickly the tumor is likely to grow and spread. 
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These grading systems are different for each type of cancer. Pathologists commonly use 
a four-degree system. The cells of grade 1 resemble normal cells and the grade 1 tumors 
are considered to behave in the least aggressive ways. The cells of grade 3 and 4 do not 
look like normal cells and tend to grow rapidly and spread fast. (National Cancer Insti-
tute 2004b.) 
An individual cancer treatment plan for patient is developed and a prognosis is pre-
dicted according to the stage and the grade of the tumor. It is important to know the 
stage and the grade of the tumor to doctors to identify the best possible treatment for 
each case. Generally it can be said that the lower the tumor grade is the better the prog-
nosis is. (National Cancer Institute 2004b.) 
 
2.2 Molecular biomarkers  
The most important thing in succeeded cancer therapy is the early detection of cancer. If 
the tumor can be identified at the earliest stage when it has not spread yet, the treatment 
will be easier and better response to treatment will be achieved. Typically tumors are 
detected not until patient gets symptoms. This fact signifies that we have still limited 
abilities in detecting cancers in their earliest stages and thus a lot to learn about it. 
(Negm et al. 2002, 288.) 
It has been discovered that there are several molecular changes occurring in developing 
tumors a long time before first actual symptoms are detected. There are different 
changes in different types of cancers. It has been shown that these alterations take place 
in gene sequences, gene expression levels and protein structure or function. (Sidransky 
2002, 210.) These alterations can be divided into genetic and epigenetic changes. Genet-
ic alterations take place in DNA. These alterations include deletions, inversions, ampli-
fication and chromosomal translocations. Epigenetic changes are independent of DNA 
sequence. Epigenetic alterations include methylation, chromatin remodelling, histone 
phosphorylation and acetylation. (Aggarwal et al. 2009, 1084.) 
These molecular alterations are considered as diagnostic markers or molecular biomark-
ers. In other words biomarkers are cellular indicators of the physiological state of a cell 
at a specific time. Active genes, protein products and other organic chemicals that cells 
make comprise the molecular signature of a cell. (Srinivas et al. 2001, 698; Sidransky 
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2002, 210.) An ideal biomarker should be easy to detect, measurable across the popula-
tion and have an early alteration with high specificity. Biomarkers can also help in de-
termining the sensitivity or resistance of cancer cells to therapies and identification of 
high-risk individuals before the onset of cancer (Srinivas et al. 2001, 698; Aggarwal et 
al. 2009, 1086.) 
 
With help of molecular biomarkers it would be easier to detect the cancer at the earliest 
stage, make the diagnosis, understand the characteristics of the cancer, determine prog-
nosis and monitor the progression of the disease and responses to selected treatments in 
future. By early detection and better understanding of the features of the cancer with 
help of molecular biomarkers it would be easier to individualize or personalize cancer 
treatments according to the type of the cancer or for patient’s needs. Through this way 
better prognosis and survival would be possible (figure 1). (Sidransky 2002, 210; Jime-
no & Hidalgo 2006, 787.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Detection and epidemiological progression of cancer. (Modified from Sri-
nivas et al. 2001, 702) 
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2.2.1 Detection of molecular biomarkers 
 
Before detection of molecular biomarkers the used biological specimen must be 
selected. These biological specimens can be tissue biopsies, body fluids, serum or 
plasma. Secondly the target for a molecular biomarker must be defined. Targets can be 
DNA, RNA or proteins, because all of them can be specific molecular biomarkers. 
(Jimeno & Hidalgo 2006, 787.) 
 
Development of novel high-throughput technologies has increased our abilities to better 
understand and investigate the molecular mechanisms of cancers (figure 2) (Negm et al. 
2002, 290). Advances in genomics and proteomics have helped us to detect these mole-
cular changes using biomarkers. Genomics is a measurement of cell’s gene expression 
profiles while proteomics detects the functioning units, proteins, of the expressed genes. 
(Srinivas et al. 2001, 700-701.) 
 
Sample material for genomics is isolated DNA. Genomics exploits DNA microarrays, 
DNA, cDNA (complementary DNA) or oligonucleotide, to provide rapid information of 
gene-expression patterns. Serial Analysis of Gene Expression (SAGE) differs from mi-
croarrays in that the expression profiles identify expressed genes and quantify their ex-
pression levels. Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) identifies 
individual transcripts synthesized from RNA. (Srinivas et al. 2001, 700.) Genomics 
provides a description of the transcriptional processes within cells (Negm et al. 2002, 
290). 
 
Sample material for proteomics is for example body fluids. Proteomics exploits two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE), development of mass 
spectrometry techniques and information technology tools to detect potential cancer-
associated proteins. (Srinivas et al. 2001, 701; Søreide et al. 2008, 44.)  
 
Immunohistochemical method for detection of biomarkers is tissue microarray which 
enables the rapid evaluation of several biomarkers by immunohistochemistry. Tissue 
microarray is also suited to further examinations such as in situ hybridization and mi-
cro-dissection techniques. (Søreide et al. 2008, 44; Tissue Microarray Facility 2009.)  
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FIGURE 2. Diagnostic paths for diagnostics of molecular biomarker in cancer detec-
tion. (Modified from Søreide et al. 2009, 44) 
 
 
2.2.2 Approved cancer biomarkers and targeted drugs 
 
There have been difficulties in identification of biomarker for most cancers and at the 
present moment there are not decent biomarkers available for most of them. In addition, 
although biomarkers have been identified it does not ensure that they would function in 
desired way. (Aggarwal et al. 2009, 1086.) Two best known, approved and currently 
used biomarkers for detection of prostate cancers and breast cancers are prostate-
specific antigen (PSA) and human epidermal growth factor receptor 2 (HER2). These 
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biomarkers are detected from urine or serum samples. For instance high serum levels of 
PSA are associated with prostate cancer, but cannot be used as a single indicator. (Negm 
et al. 2002, 290; Aggarwal et al. 2009, 1086.) 
 
Several targeted anticancer drugs have been developed and approved for treatments of 
different kinds of cancers at present. A common feature in all of them is however uncer-
tainty about patients’ responses to these drugs. Trastuzumab (Herceptin) is a monoclon-
al antibody which is raised against an epitope in the intracellular domain of HER2. It is 
discovered that HER2 gene is present in 20-25% of breast cancers. The mechanism, 
how herceptin affects tumors is not fully understood. It has been suggested that hercep-
tin might inhibit tumor growth by downregulation of receptors or by reducing the num-
ber of blood vessels of the tumor. Disadvantage of herceptin is the fact that patients of-
ten develop resistance to it after one year. Herceptin is well-tolerated drug and it is often 
used in combination with other chemotherapy drugs. (Aggarwal et al. 2009, 1086, 
1088.) 
 
Another targeted anticancer drug is avastin (Bevacizumab) which is a recombinant hu-
man monoclonal antibody raised against human vascular endothelial growth factor 
(VEGF) for metastatic colorectal cancers. It has been discovered that VEGF is ex-
pressed in half of the colorectal carcinomas. The effects of avastin in patients are un-
clear, but the disruption of tumor blood vessels is possible. Gleevac (Imatinib mesylate) 
is designed for treatment of chronic myeloid leukemia (CML) after normal treatment 
with interferon-α (IFN-α) have been failed. It has been reported to have only few minor 
side effects. (Aggarwal et al. 2009, 1090.) 
 
According to Aggarwal et al. (2009, 1091-1092) individualized or personalized medi-
cine for cancer treatment is important for two reasons: to increase efficiency and to de-
crease toxicity of drugs for patients. This is because some patients may be under-treated 
and some over-treated whereas some may not respond to treatments at all and some may 
suffer from toxic side-effects. The main idea of personalized treatment is to give the 
right drug at the right dose to the right patient. (Aggarwal et al. 2009, 1091-1092.) 
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2.3 Endosialin 
 
Endosialin (alternatively named as TEM1 or CD248) was originally found in 1992 and 
described as the antigen of FB5 mouse monoclonal antibodies raised against cultured 
human fetal fibroblasts. At first it was considered as a specific marker of tumor blood 
vessels because of its expression in endothelial cells of malignant human cancers that 
were analyzed by immunohistochemistry. In analysis normal blood vessels and tissues 
lacked the FB5 expression. The protein was named as endosialin and the gene was lo-
cated to chromosome 11q13. (Rettig et al. 1992, 10832.)  
 
In 2000 gene expression patterns of human endothelial cells derived from blood vessels 
of normal and cancerous colorectal tissues were compared. Expression patterns were 
analyzed with SAGE-method. Many gene transcripts were found to be overexpressed in 
tumor endothelium. These genes were named as tumor endothelial markers (TEMs). 
Endosialin was independently discovered when Tem1 gene was found to encode endo-
sialin. (St. Croix et al. 2000, 1198, 1199.) 
 
At present endosialin is described as a type I cell surface glycoprotein having a single-
pass transmembrane α-helix. Endosialin consists of a 90 kDa core protein, but the mole-
cule is highly modified by O-linked glycosylation comprising the mature form of 165 
kDa. (Christian et al. 2001, 7408.) It has also been found that endosialin is expressed by 
tumor stromal fibroblasts and tumor blood vessel-associated perivascular cells (peri-
cytes) rather than endothelial cells by themselves like earlier has been suggested (Mac-
Fadyen et al. 2005, 2569.) 
 
 
2.3.1 Molecular structure of endosialin 
 
Information of the molecular structure of endosialin was gained when partial amino acid 
sequence of endosialin was unraveled and its full-length cDNA was cloned. It became 
clear that endosialin molecule comprises of 2274 base pairs with an open reading frame 
and that the endosialin cDNA encodes for 757 amino acids core protein. According to 
bioinformatic evaluation endosialin can be classified as a C-type lectin-like protein. 
(Christian et al. 2001, 7408.) 
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Endosialin is composed of several functional domains (figure 3). A more N-terminal 
globular portion of the molecule consists of amino acids 30-360 and includes a N-
terminal signal leader peptide, a C-type lectin domain, a Sushi domain and three endo-
thelial growth factor (EGF) domains. A more C-terminal region consists of amino acids 
361-757 and includes a mucin like region, a transmembrane region and a short cytop-
lasmic tail. N-terminal segment of endosialin was found to share 39% sequence identity 
to human thrombomodulin (CD141) and 33% sequence identity with human comple-
ment receptor C1qRp (Christian et al. 2001, 7410-7411.) 
 
 
 
 
 
FIGURE 3. Domain architecture of endosialin molecule. The N-terminal signal leader 
peptide (N), the C-type lectin domain (C), The Sushi domain (S) and three EGF repeats 
(EGF) followed by the mucin-like region (MUCIN), the transmembrane section (TM) 
and the short cytoplasmic tail (CYT). (Modified from Christian et al. 2001, 7412) 
 
 
2.3.2 Expression of endosialin 
 
Despite of the fact that endosialin is expressed in tumors the expression has been de-
tected also in normal endothelium. Normal expression of endosialin has been examined 
in developing mouse embryos, newborns and adults by immunohistochemistry and in 
messenger RNA (mRNA) levels by RT-PCR. Strong expression of endosialin was de-
tected in developing mice embryos. In the embryos endosialin was expressed by fibrob-
lasts and pericytes of developing vasculature. However there was a significant loss of 
expression in adults. Endosialin is thus downregulated during development of mouse 
leading to a conclusion that in normal adult tissues endosialin is not expressed. Expres-
sion studies of endosialin by RT-PCR revealed that expression levels of endosialin 
mRNA increase during the whole embryonic stage and rapidly decrease in newborns 
and adults.  (MacFadyen et al. 2007, 363, 365, 367; Rupp et al. 2006, 1,4.) 
 
In different studies the expression of endosialin was detected in various types of human 
tumors in vivo and in vitro. In a study of human brain tumors by immunohistochemistry 
1 360 757 
N C S EGF MUCIN TM CYT EGF EGF 
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the expression of endosialin was localized to pericytes of blood vessels and stromal fi-
broblast cells. Normal tissue was negative for endosialin. The immunostaining reaction 
was detected in both primary and metastatic tumors. Brady et al. 2004, 1274, 1283.) 
Expression of endosialin in human breast tumor specimens by immunohistochemistry 
was studied by generating a panel of monoclonal antibodies against extracellular do-
main epitopes of human fibroblast cell surface proteins. The expression of endosialin 
was detected on tumor stromal fibroblast cells in every examined section. (MacFadyen 
et al. 2005, 2573.) Similar results were reported with human ovarian tumors, human 
colon carcinoma biopsies, cultured human neuroblastoma cells and mesenchymal stem 
cells. (Christian et al. 2008, 487, 493; Bagley et al. 2008, 187.) 
 
An extensive and valuable study was made when expression of endosialin in Tem1 
knockout (KO) and wild type (WT) mice was investigated. Knockout is a genetic tech-
nique by which function of a selected gene is completely inactivated or deleted (Alberts 
et al. 2008, 566). Wild-type is normal nonmutant form of organism. The study firstly 
showed that Tem1 KO mice developed normally and were completely healthy having a 
normal vasculature and wound healing capability. (Nanda et al. 2006, 3351.) 
 
Human colorectal cancer cells were transplanted to abdominal sites of KO and WT 
mice. Interestingly there was a reduction in tumor growth, invasiveness and metastasis 
in tumors transplanted to abdominal sites of KO mice compared to WT mice. It was 
demonstrated that Tem1 gene is not a requirement for tumor angiogenesis, but optimal 
growth, invasion and metastasis of tumors depend on the expression of endosialin. Sta-
tistically survival of KO mice of tumor growth period was 89% compared to 11% for 
WT mice. In addition tumors in KO mice grew more slowly with fewer metastases and 
smaller tumor volume. (Nanda et al. 2006, 3351, 3352.) 
 
 
2.3.3 Functions of endosialin  
 
The function of endosialin is not known for certain, but there are few reasonable sug-
gested functions. The main function of endosialin is still under high investigation, be-
cause for example molecular functions and intracellular signaling pathways are still 
unknown. A full understanding of functions of endosialin in normal development and 
cancer is not possible without understanding first its molecular mechanisms and func-
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tions that control its expression. (Rupp et al. 2006, 10; Ohradanova et al. 2008, 1348, 
1353.) 
 
The expression of endosialin is localized to the cell surface. For this reason it is ex-
pected that the function of endosialin is mediated through direct cell to cell interactions 
rather than through paracrine system. (Nanda 2006, 3354.) Endosialin is restricted to 
fibroblasts where it presumably functions as a cell surface receptor to bind ligands 
found in extracellular matrix (ECM) (McFadyen et al. 2005, 2574). 
 
One suggested function of endosialin is the interaction with ECM proteins. In other 
words it is suggested that endosialin can adhere to the supporting proteins of ECM such 
as collagen and fibronectin and thus mediate the cell adhesion and migration through 
ECM. Interactions between endosialin and fibronectin, and collagen I and collagen IV 
have been found. These ECM proteins serve as ligands for endosialin. (Tomkowicz et 
al. 2007, 17969.) 
 
 
2.3.4 Endosialin as a molecular biomarker 
 
Expression of endosialin is often linked to angiogenesis. Firstly because endosialin is 
expressed in pericytes that are closely connected to endothelial cells during formation of 
blood vessels and secondly because of the expression of endosialin found in vasculature 
of developing mice embryos. (MacFadyen et al. 2007, 363; Bagley et al. 2008, 180.) 
Angiogenesis occurs during normal physiological development and under pathologic 
conditions like tumor growth (Bagley et al. 2008, 2536). Mostly it is a consequence of 
hypoxia in developing tissue. It has been found that hypoxia induces the expression of 
endosialin. This induction occurs through a mechanism that involves hypoxia-inducible 
factor-2 (HIF2) which has been earlier independently linked to regulate a part of genes 
involved in angiogenic responses. (Ohradanova et al. 2008, 1348, 1353.) 
 
It has been suggested that blood vessel development may involve endothelial precursor 
cells (EPC). On the other hand it means that angiogenic process in cancer can involve 
EPC that express endosialin. It has been found that endothelial genes are up-regulated in 
both tumor vasculature and in EPC cells. Through investigations it has been observed 
that the expression of endosialin increased in EPC cells compared to mature endothelial 
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cells. This indicates that endosialin is connected to the early stages of angiogenesis. 
(Bagley et al. 2008, 2536.) 
 
It has been shown that endosialin plays an important functional role not only in angi-
ogenesis but also in tumor progression and in tumor stroma formation, because KO 
mice dramatically changed tumor growth patterns and reduced metastasis. Thus it has 
been suggested that interactions between endosialin and tumor cells may induce the 
production of other proteins in tumor cells or stroma that can help the tumor to grow 
and invade surrounding tissues. (Nanda et al. 2006, 3354.) 
 
One specific ligand for endosialin has been identified. An extracellular ligand for spe-
cific endosialin interaction was named as Mac-2 BP/90K. It has been demonstrated that 
interaction of endosialin and Mac-2 BP/90K ligand mediates and regulates the adhesion 
and migration of tumor cells that express endosialin in ECM of tumor. Through experi-
ments it has been shown that expression of Mac-2 BP/90K ligand correlates with distant 
metastases. Therefore Mac-2 BP/90K ligand seems to be functionally linked to tumor 
development and progression. (Becker et al. 2008, 3059, 3064-3065.) 
 
 
2.3.5 Therapeutic prospects 
 
Generation of anti-endosialin antibodies is widely ongoing. Antibodies, inhibitors and 
antibody-toxin conjugates are generated to, either directly or indirectly, influence the 
angiogenesis through different mechanisms. In addition single-chain antibody fragments 
directly towards the extracellular domain of endosialin are also produced. Antibody 
targeting therapies are evolving field in cancer treatment with a view to generate mod-
ern, effective and strictly targeted cancer therapies. (Bagley et al. 2008, 187; Bagley et 
al. 2008, 2544.) 
 
Anti-endosialin antibodies may have potential for prevent migration of tumor cells and 
thus prevent the development of cancer. It could also be possible, with appropriate 
agent, to interfere with the growth of blood vessels during angiogenesis and prevent 
tumor development. Inhibition of pericyte function by targeting endosialin with a mo-
noclonal antibody may provide a new strategy in which vascular destabilization and 
inhibition of angiogenesis may be possible. On the other hand the disruption of peri-
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cyte-endothelial cell interactions could also serve a link to interfere the whole develop-
ment of cancer. (Bagley et al. 2008, 187.) 
 
In practice for example blocking the migration of EPC cells with anti-endosialin antibo-
dies could be useful in preventing cancer growth and early angiogenesis (Bagley et al. 
2008, 2536). On the other hand by targeting the endosialin-Mac-2 BP/90K ligand com-
plex it might prevent the adhesion and migration of tumor cells and that way also pre-
vent the metastatic spread of cancer (Becker et al. 2008, 3059).  
 
 
2.4 Immunohistochemical methods 
 
Immunohistochemistry is a routine tool in many laboratories. It combines anatomical, 
immunological and biochemical understanding and techniques to identify specific tissue 
components by specific binding between labeled antibodies and antigens. Immunohisto-
chemistry provides for visualization the distribution and localization of cellular compo-
nents within tissue. (Thermo Scientific 2009.) 
 
Immunohistochemistry is a traditional diagnostic tool in identification and detection of 
cancer. These techniques are important for prediction of tumor behavior and prognosis. 
(Srinivas et al. 2001, 698.) Basic immunohistochemical examination includes sample 
obtainment, tissue processing, production of thin tissue sections, staining and micro-
scopic analysis (figure 4). 
 FIGURE 4. The steps of typical immun
 
 
2.4.1 Tissue sample obtainment
 
For diagnosing diseases it is remarkably important to obtain small tissue samples from 
human body. There are lots of simple and different techniques for the s
ment. Tissue sample can be obtained from seve
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by direct needle biopsy whereas samples from respiratory tract, aliment
nary tract can be obtained by endoscopic biopsy using endoscopic tubes. Scalpels are 
suitable for obtaining samples from directly accessible tissues such as skin, mouth, l
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The use of isopentane and liquid nitrogen for rapid freezing has been found to produce 
best sections. After freezing tissue samples are ready for sectioning in cryostat, which is 
a special microtome, and staining with appropriate dyes. Frozen section technique can 
also be exploited when cellular lipids and enzymes are detected from tissues, because 
regular tissue processing would easily destroy them. (Carson 1997, 40-41, 52-52; Jun-
queira & Carneiro 2003, 2; Ross & Pawlina 2005, 4.) 
 
 
2.4.2 Fixation 
 
Most tissues are fixed before examination under microscope. Aims of the fixation are to 
prevent autolysis and bacterial attack, to prevent changes in shape or volume in tissues 
during any subsequent steps and to preserve tissues in a condition as close in their living 
state as possible. Fixation is performed by stabilizing proteins either by chemical (fixa-
tive solutions) of physical (heat, microwaves) means. Primary methods for fixation are 
the use of one or more chemical reagents. (Carson 1997, 2; Bancroft & Stevens 1999, 
23.) 
 
Fixative solutions are mostly classified as additive or nonadditive and coagulant or non-
coagulant. Additive fixatives such as formaldehyde, glutaraldehyde, picric acid and os-
mium tetroxide change the tissue by chemically linking themselves to it. Nonadditive 
fixatives like acetone and alcohols do not add themselves to the tissue but function 
through precipitation or coagulation of proteins. Coagulant fixatives such as alcohol and 
picric acid create a network in tissues allowing solutions to easily penetrate into the in-
terior of the tissue. Noncoagulant fixatives like formaldehyde, glutaraldehyde and os-
mium tetroxide create a gel making the penetration of solutions difficult. (Carson 1997, 
2-3; Bancroft & Stevens 1999, 23-24.) 
 
The most widely used fixative solution is formaldehyde. Commercially available solu-
tions under trade name formalin contain 34-40% gas by weight. Formaldehyde is com-
monly used as neutral buffered formalin which contains 40% formaldehyde buffered to 
pH 7 with phosphate buffer. In aqueous solutions formaldehyde exists as its monohy-
drate, methylene glycol. Formaldehyde is additive and noncoagulant fixative and causes 
proteins to become insoluble by reacting with amino groups on the side chains of amino 
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acids. The reaction is reversible and pH-dependent. (Carson 1997, 8-10; Bancroft & 
Stevens 1999, 24-25, 35.) 
 
 
2.4.3 Tissue processing 
 
Tissue processing includes dehydration, clearing and embedding steps performed either 
manually or automated. Tissue processing is at present mainly automated. The auto-
mated process is similar to manual processing and contains same steps. First tissue 
processing step is called dehydration. It means removal of aqueous fixative fluids like 
water in tissues because embedding media will not infiltrate tissue containing any water. 
Dehydration is the most critical step of tissue processing because faults in this step are 
difficult to correct later (Bancroft & Stevens 1999, 53.) The most widely used dehydrat-
ing agent is ethanol. It is hydrophilic and miscible with water and with many organic 
solvents. It functions by attracting water from the tissues. Ethanol is delicate causing 
very little damage to tissues. Dehydration process is performed with series of increasing 
concentrations of ethanol starting from 70% and ending to absolute alcohol. (Carson 
1997, 26-27; Bancroft & Stevens 1999, 49.) 
 
Dehydration step is followed by clearing step. Clearing agents must be miscible with 
both the dehydrating agent (ethanol) and the embedding medium, frequently paraffin. 
The most widely used clearing agent is xylene. It removes the ethanol used in dehydra-
tion step, gives tissues a translucent appearance and makes tissues more receptive to the 
embedding medium. Too long clearing time hardens tissues leading to problems with 
tissue processing. (Carson 1997, 28; Bancroft & Stevens 1999, 50.) 
 
Subsequently tissues are infiltrated with supporting embedding medium. The purpose of 
embedding is to hold proper relationship between cells and intracellular structures when 
sectioned. The most popular embedding medium is paraffin wax which is an inert mix-
ture of hydrocarbons. The melting point has an effect on properties of paraffin wax. 
Usually waxes of melting point 54-58°C are used. (Carson 1997, 31-32; Bancroft & 
Stevens 1999, 51-52.) 
 
Embedding is performed usually in a vacuum oven by immersing tissues to melted pa-
raffin. Temperature of paraffin should be 2-4°C above its melting point. Vacuum helps 
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paraffin to infiltrate tissues. When immersing tissues to embedding medium paraffin 
penetrates tissues and removes residual air bubbles. Exposure to embedding medium is 
continued until air bubbles do not anymore come up. (Carson 1997, 32; Bancroft & Ste-
vens 1999, 52-53.) 
 
Tissue processing is followed by blocking which means enclosing tissue in paraffin 
wax. Blocking can be counted as a part in tissue processing. Blocking system comprises 
of melted paraffin wax dispenser, cold plate and heated area for molds and infusion of 
blocks. In blocking melted paraffin wax is dispensed into a preheated mould. Tissue 
specimen and tissue cassette are placed in mould. Mould is filled with melted paraffin 
wax, transferred to cold plate and allowed to cool down and solidify into block. Mould 
is removed from solidified block and block is ready for sectioning. (Bancroft & Stevens 
1999, 52.) 
 
There are few occasions when paraffin processing cannot be used in tissue processing 
and blocking: i. processing agents remove or damage investigated tissue components, ii. 
thinner sections are desired, iii. heat (with paraffin 56-60°C) would affect or damage 
tissue or iiii. paraffin do not offer as hard support as needed. Substitute processing and 
blocking agents for paraffin are for example other waxes like polyethylene glycol and 
resins like acrylic. For instance resins play an important role in electron microscopy 
when thinner sections and higher resolutions are needed. (Bancroft & Stevens 1999, 56-
57.) 
  
 
2.4.4 Production of tissue sections 
 
So that the examination under microscope can take place thin tissue sections needs to be 
produced out of tissue blocks. Microtomes are instruments that allow production of sec-
tions with adjusted thickness; usually 5µm. Rotary microtomes are the most popular 
ones and the most suitable choice for paraffin embedded tissues. (Bancroft & Stevens 
1999, 58.) 
 
Requirements for thin tissue sections are proper temperature of the block, a sharp blade 
and suitable sectioning speed. Disposable blades provide a very sharp cutting edge and 
have replaced the old steel knives. The best sectioning speed depends on many qualities 
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such as softness of the tissue, air temperature, humidity, size of tissue and thickness of 
the sections. Unsatisfactory sections depend primarily on blunt blade or not cold enough 
temperature of block. (Bancroft & Stevens 1999, 60.) 
 
 
2.4.5 Staining process 
 
Completely dry tissue sections are deparaffinised before staining. Deparafinisation 
means removal of paraffin found in tissue sections. Any water left in tissue will lead to 
incomplete deparaffinisation and uneven staining. Deparaffinisation process is started 
with xylene, followed by series of decreasing consentrations of alcohols and ended up 
in distilled water. Xylene will remove paraffin while alcohols will remove xylene from 
sections. (Carson 1997, 57.) 
 
Cells and their intracellular material are generally colorless. Staining is needed to vi-
sualize localization of cellular component within tissues in the light microscope. Stain-
ing can be made manually or automatically using some sort of staining automat. Stain 
uptake is due to dye-tissue or reagent-tissue affinities. Affinity describes the attractive 
forces which bind dye to tissue. On the other hand if tissue has a high affinity for a dye 
it usually becomes intensively stained. The dye is bound to tissue mostly by ionic, cova-
lent or hydrogen bonds with help of van der Waals attractions. (Bancroft & Stevens 
1999, 81; Histology and cell biology 2003.) 
 
The dyes bind to certain tissue constituents selectively depending on the nature of the 
dye and the chemical composition of the tissue. There are positive and negative net 
charges found both in tissue components and dyes. If a dye ion has positive net charge it 
is cationic and also called a basic dye. If a dye ion has negative net charge it is anionic 
and also called an acid dye. If a tissue component has negative net charge, it will have 
affinity for basic dyes and vice versa.  For example DNA and RNA will stain with basic 
dyes whereas cytoplasm and collagen stain with acid dyes. Usually more than one dye is 
used in staining process for increase of clearance. The first dye stains wanted tissue 
components selectively while the second dye is used as contrasting color to stain other 
tissue or cellular components. This is called counterstaining. (Carson 1997, 89; Histolo-
gy and cell biology 2003.) 
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The following step for staining process is another dehydration process. The intention of 
dehydration is to remove water from tissue with series of increasing concentrations of 
alcohols ending up in xylene, which removes remaining alcohol. After dehydration cov-
er glasses are applied to stained sections using some type of mounting medium. The 
step is called mounting. Cover glasses help to preserve stained sections and enable bet-
ter microscopic analysis. (Carson 1997, 26, 107.) 
 
 
2.4.6 Dyes 
 
There are lots of different dyes. However all dyes are organic compounds and often also 
benzene derivatives. According to Carson (1997, 89) a group in a dye molecule confer-
ring the color is called a chromophore. A common feature for every chromophore is that 
they are easily reduced. A chromogen is a benzene derivative containing a chromophor-
ic group. A compound containing a group of chromophore or chromogen may not nec-
essarily act as a dye and be able to combine with the substance to be colored. An ioniz-
ing group called auxochrome, most commonly amino group, is in some cases required 
to enable the dye to link to the tissue. (Carson 1997, 87, 89.) 
 
An example of dyes is hematoxylin which is a natural color extracted from the heart-
wood of the tree Haematoxylin campechianum and used for nuclear staining. Hematox-
ylin is not itself a dye but the oxidation product hematein acts as a natural dye. Oxida-
tion product can be produced from hematoxylin either with natural oxidation or chemi-
cal oxidation. Chemical agents used for oxidation are for example sodium iodate (May-
er’s hematoxylin) or mercuric oxide (Harris’ hematoxylin). (Carson 1997, 90-92.) 
 
Hematein is anionic and has a poor affinity to tissue. That is why a presence of mordant 
is needed to nuclear staining. The most widely used mordants for hematoxylin are alu-
minium, iron and potassium salts. The mordant enables the binding of dye-mordant 
complex to anionic tissue sites as chromatin and nuclei. Hematoxylin is the most widely 
used in nuclear counterstaining, because it provides a good distinction between nuclei, 
cytoplasm and extracellular constituents. (Bancroft & Stevens 1999, 99, 101; Histology 
and cell biology 2003.) 
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2.4.7 Immunostaining techniques and enzyme labels 
 
By immunohistochemical techniques it is possible to identify tissue constituents, anti-
gens, by exploiting the specific interactions between antibodies and antigens.  Immuno-
histochemical staining methods are based on the use of labeled antibodies. Labels are 
used for visualization of antigens found in tissues. Antibodies can be labeled either with 
enzymes, colloidal metals, fluorescent labels or radio labels. Enzymes are the most 
widely used labels in immunohistochemistry. Commonly used enzymes for labeling are 
horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase and beta-D-
galactosidase. Incubation of enzyme-conjugated antibodies in presence of substrate and 
chromogen produces stable and colored reaction product suitable for light microscopic 
examination. (Bancroft & Stevens 1999, 438.) 
 
There are various immunostaining techniques used to detect presence of antigen in sam-
ple. However the most common techniques are direct and indirect methods. In direct 
technique label is conjugated to the primary antibody which detects antigens found in 
tissue. The advantage of direct technique is simplicity and the disadvantage low sensi-
tiveness. Indirect method uses two antibodies, primary and secondary, to detect antigens 
(appendix 1, figure 1). Primary antibody is unlabeled and detects the antigens found in 
tissue. Labeled secondary antibody is followed against the primary antibody. Indirect 
technique is more sensitive technique compared to direct technique. (Bancroft & Ste-
vens 1999, 439, 441-442.) 
 
Immunohistochemical staining using enzyme-labeled antibodies results from the reac-
tion between enzyme and its substrate. In the reaction soluble substrate with enzyme 
produces an insoluble and colored reaction end-product. Enzymes can be used in immu-
nohistochemical staining instead of dyes. The intensity of formed colored reaction end-
product should correlate to the concentration of the primary antibody and the tissue an-
tigen. Enzymatic activity depends on concentration of enzyme and substrate, buffer, pH, 
temperature and light source. Variety of enzyme conjugated antibodies and chromogens 
are commercially available. (Thermo Scientific 2009.) 
 
Large and significant group of enzymes used in immunostaining are oxidoreductases. 
This category includes oxidases, peroxidases, dehydrogenases and diaphorases. Perox-
idases catalyse oxidation of its substrate by removing hydrogen. The hydrogen acceptor 
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for the hydrogen atoms is always molecular oxygen leading in the formation of water, 
chemical reaction 1A. In the oxidation reaction of HRP conjugated secondary antibody 
HRP is an enzyme while hydrogen peroxidase is a substrate and 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) is a chromogen. Reaction produces oxidized DAB, insoluble 
dark brown colored reaction end-product visible for naked eyes and suitable for exami-
nation under light microscope, chemical reaction 1B. (Carson 1997, 254.)   
 
 
 
 
 
 
 
 
CHEMICAL REACTION 1. Enzymatic reactions of peroxidases. A. Oxidation reaction 
of peroxidases. B. Enzymatic oxidation reaction of HRP involving substrate and chro-
mogen. (Modified from Carson 1997, 254; Krysko et al. 2006, 2020) 
 
In enzyme-labeled immunostaining it is important to block the endogeneous peroxidase 
activity and reactive sites found in tissues. If endogeneous peroxidase activity is not 
blocked, cellular components such as enzymes could result in unwanted signals and 
false positive staining result. Blocking of reactive sites found in tissues helps to avoid 
nonspecific binding of antibodies and also prevents false positive staining result. In 
HRP-technique the most widely used blocking agent for endogeneous peroxidase activi-
ty is hydrogen peroxidase and for reactive sites normal serum or colostrum. (Thermo 
Scientific 2009.) 
 
 
  
HRP + H2O2 + DAB HRP + 2H2O2 + Oxididized DAB,
dark brown product
4H+ + 4e
-
+ O2 2H2O
A 
B 
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3 AIMS OF THE STUDY 
 
 
This study was focused on poorly known cancer associated protein, endosialin. The aim 
of the study was to investigate expression of endosialin in different human tumors and 
to identify the expression of endosialin by immunostaining. Specific aims of this re-
search were 
 
i. to characterize the function and suitability of novel endosialin specific anti-
bodies for immunostaining, 
 
ii. to investigate endosialin expression levels in tumor specimens. 
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4 MATERIALS AND METHODS 
 
 
4.1 Sample material 
 
Sample material for this study consisted of considerably large amount of tissue samples. 
Samples were selected from as many different tissues as possible in order to have a 
highly presentable sample material so that description of endosialin expression pattern 
would be possible in large scale. Tissue specimens from colon and pancreas were ob-
tained from Jyväskylä central hospital. Tissue specimens from liver were obtained from 
Hospital district of Helsinki and Uusimaa. Tissue specimens from the brain, colon, skin, 
esophagus, antrum, duodenum, corpus and rectum were obtained from Tampere univer-
sity hospital. Diagnosis with every specimen was known and the tumor grade of brain- 
and colon specimens was also defined. 
 
All of the samples obtained from Jyväskylä central hospital and Hospital district of Hel-
sinki and Uusimaa were formalin fixed and paraffin embedded, already sectioned and 
mounted on microscopic glass slides. The samples from Tampere university hospital 
were formalin fixed and paraffin embedded tissue blocks. For these tissue specimens 
sectioning and drying was performed before staining process. 
 
 
4.2 Sectioning and drying 
 
Before sectioning of tissue blocks both hot and cold water baths were filled with distill-
ed water and the blocks were cooled down to proper temperature on a cold plate (+4°C). 
Sectioning was performed with microtome (Microm, GmbH, HM310, Walldorf, Ger-
many) using disposable blades. Tissue block was placed on microtome so that the blade 
reached the whole surface of the block. Extra paraffin was trimmed away with thickness 
adjusted to 20µm. Before actual sectioning the thickness was adjusted to 5µm which 
was the desired thickness of sections.  
 
Tissue sections were gained by rotating the microtome screw manually. The cut sections 
were floated onto the cold water bath containing room temperature water. By floating 
out sections the wrinkles were straightened. Sections were transferred to hot water bath 
 (+45°C) to achieve the expansion of sections to their original sizes. From hot water bath 
sections were transferred to microscopic g
night. Drying of the sections was carried out in an oven (+60°C). Drying t
proximately two hours. 
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Staining was performed according to the manufacturer’s protocol using fully computer 
operated automatic staining device, autostainer (model: 480; Lab Vision Products, 
Thermo Fisher Scientific, Runcorn, Cheshire, United Kingdom). Staining program was 
created with computer (table 1 and appendix 3, figure 2). Dispense volume of reagents 
was adjusted to 100µl. When the staining program was approved the computer reported 
the needed volumes of reagents, distilled water and Tris buffered saline with tween 
(TBS-Tween) used in immunostaining. Reagents used in staining process are 
represented in a form of reagent layout map (appendix 3, figure 3). 
 
Reagents were put to autostainer tubes according to the reagent lay out map. Endosialin 
monoclonal antibody II-50/3 was diluted 1:5 in primary antibody diluent. Endosialin 
monoclonal antibody VIII-16 was undiluted. Slides were transferred from staining 
chamber to autostainer racks and moistened with TBS-Tween buffer. When prime 
pumps for distilled water and TBS-Tween buffer were done the autostainer was ready to 
start the programmed staining process. Between reagent applications staining waste was 
rinsed from slides either with distilled water or TBS-Tween buffer. When staining 
process was ready the slides were transferred back to distilled water containing staining 
chamber.  
 
 
TABLE 1. Immunostaining program for detection of endosialin by indirect immunos-
taining and enzyme-labeled antibodies. 
Reagent Function is to Time (min) Dilution 
H2O2 block endogeneous peroxidase 5 3% 
Colostrum block non-specific binding sites 10 1:5 
Primary antibody bind to epitope of antigen 30 1:5 / − 
Post block block mouse immunoglobulins 20 − 
Secondary antibody bind to the primary antibody 30 − 
DAB form a brown precipitate 5 1:30 
CuSO4 strengthen and brighten up reaction 5 0,5% 
HEMA nuclear counterstain 1 1:3 
 
 
Dehydration process started from distilled water containing staining chamber. Reagents 
were same as were used in deparaffinisation process but in reverse order. The sledge 
containing slides was transferred from one chamber to another (figure 6). Cover glasses 
 were applied on stained tissue sections. A mounting medium (Pertex, xylene
Histolab products AB, Göteborg, Sweden) is used to attach cover glasses. Few drops of 
mounting medium were pipetted onto the tissue sections and cover glasses were placed 
onto tissue. Air bubbles were remove
sections. Slides were allowed to dry before microscopic analysis.
FIGURE 6. The arrangement of dehydration process. 
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5 RESULTS 
 
 
5.1 Function of novel endosialin monoclonal antibodies 
 
Both endosialin monoclonal antibodies II-50/3 and VIII-16 showed good expression in 
stained tissue specimens. The used staining protocol and dilutions under both endosialin 
antibodies were suitable. It appeared that there was variation in staining reactivity rather 
between tissue types than between antibodies. Antibody II-50/3 generally showed 
slightly weaker staining reactivity. Staining intensity was clearly stronger in brain tu-
mors and in skin specimens than it was in colorectal cancer, pancreatic cancer or in he-
patobiliary lesions. Background staining was overall insignificant and nuclei counters-
taining was successful.  
 
It became evident that staining reactivity was generally lower in normal tissues com-
pared to cancerous tissues with both antibodies. This result was the most clearly visible 
in nervous tissues of the brain specimens as shown in figures 9 and 10, where brain tu-
mors showed clearly stronger staining intensity than normal brain. There were some 
differences in staining reactivity between antibodies II-50/3 and VIII-16. Interestingly 
for example in normal skin antibody VIII-16 showed stronger intensity but in normal 
colon the intensity was vice versa (figures 7A and B). There was medium correlation in 
staining reactivity within two antibodies in normal skin and in normal colon tissues. 
Staining results in normal skin showed not statistically significant medium correlation 
between antibodies (Spearman r2=0,569, p=0,200) (figure 7A). Staining results in nor-
mal colon showed highly statistically significant medium correlation between antibodies 
(Spearman r2=0,493, p=0,0007) (figure 7B). 
 
 
 
 
 
   
 
 
 
34 
 
 
 
 
 
 
 
 
 
FIGURE 7. Expression of endosialin in normal tissues. A. Normal skin and B. Normal 
colon. 
  
 
5.2 Expression of endosialin in tumors 
 
 
5.2.1 Endosialin in brain tumors 
 
Immunostaining reaction in brain tumor specimens was overall quite intense (figures 9 
and 10). Positive reaction was detectable in both nervous tissues and blood vessels of 
the specimens. It showed that staining intensity was generally stronger in blood vessels 
than in nervous tissues with either of the endosialin antibodies. Moreover staining inten-
sity was the strongest in blood vessels stained with antibody VIII-16 (figure 10D). 
 
Mean intensity of blood vessels stained with antibody II-50/3 varied between 1,2 ± 0,1 
(SEM) – 2,0 ± 0,0 (SEM) (standard error of mean) with different types of brain tumors 
(figure 8B). Mean intensity of blood vessels stained with antibody VIII-16 varied be-
tween 1,9 ± 0,2 (SEM) – 2,3 ± 0,3 (SEM) with different types of brain tumors (figure 
8D). In every occasions the most intense staining could be seen with gliosarcoma, but 
the case number (n=3) may have had an effect on the result (figure 8). 
 
There were two statistically significant differences in endosialin expression between 
different brain tumor types. These differences were observed with antibody VIII-16 
stained nervous tissues. The difference in endosialin expression between glioblastoma 
multiforme and gliosarcoma was statistically significant (p=0,04, unpaired t-test). Other 
statistically significant difference (p=0,02, unpaired t-test) in endosialin expression was 
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observed between diffuse astrocytoma and gliosarcoma. No statistically significant dif-
ference in endosialin expression (p>0,05, unpaired t-test) was observed between nerv-
ous tissues or blood vessels stained with antibody II-50/3 and blood vessels stained with 
antibody VIII-16.  
 
Both nervous tissue and blood vessels showed the most intense immunostaining reac-
tion with both endosialin antibodies under anaplastic astrocytoma, grade 3. However no 
statistically significant difference (p>0,05, one-way analysis of variance) was observed 
in the endosialin immunostaining reactions between different tumors grades, data not 
shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8. Immunostaining reactivity in brain tumors. A. Nervous tissue stained with 
antibody II-50/3, B. Blood vessels stained with antibody II-50/3, C. Nervous tissue 
stained with antibody VIII-16 and D. Blood vessels stained with antibody VIII-16. 
GBM = Glioblastooma multiforme, AA = Anaplastic astrocytoma, DA = Diffuse astro-
cytoma and GS = Gliosarcoma. 
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FIGURE 9. Endosialin in brain tumors, stained with endosialin antibody II-50/3. A. 
Normal brain, B. Anaplastic astrocytoma, C. and D. Glioblastoma multiforme and E. 
Gliosarcoma. Arrows represent blood vessels. 
   
37 
 
 
FIGURE 10. Endosialin in brain tumors, stained with endosialin antibody VIII-16. A. 
Normal brain, B. Anaplastic astrocytoma, C. and D. Glioblastoma multiforme and E. 
Gliosarcoma. Arrows represent blood vessels. 
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5.2.2 Endosialin in colorectal cancers 
 
There was lots of variation in immunostaining intensity in colorectal cancer specimens. 
Sometimes normal colon showed very intense staining but elsewhere staining intensity 
was negative. All colorectal cancers behaved similarly. For example a comparison be-
tween two normal colon specimens showed both weak and very intense staining as 
shown in figures 13A and B and 14A and B. On the other hand a comparison between 
colorectal cancers microsatellite stable (MSS) and gastrointestinal stromal tumor 
(GIST) showed same kind of result as shown in figures 13E and G and 14E and G. Inte-
restingly it was also noticed that human normal colon smooth muscle staining was very 
intense with both endosialin antibodies (figures 13C and 14C).  
 
Comparison of immunostaining reactivity between colorectal cancers showed the most 
intense staining with both endosialin antibodies in microsatellite instable (MSI) speci-
mens (figures 11A and B). Mean immunostaining intensity of MSI with antibody II-
50/3 varied between 1,533 ± 0,2 (SEM). Mean immunostaining intensity of MSI with 
antibody VIII-16 varied between 1,688 ± 0,2 (SEM). These results indicated that overall 
immunostaining intensity was again slightly more intense with antibody VIII-16. 
 
 
 
 
 
 
 
 
 
 
FIGURE 11. Immunostaining reactivity in colorectal cancers. A. Stained with antibody 
II-50/3 and B. Stained with antibody VIII-16. MSS = Microsatellite stable, MSI = Mi-
crosatellite instable and HNPCC = Hereditary nonpolyposis colorectal cancer. 
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antibodies. The differences in endosialin expression between MSS and MSI were statis-
tically significant with both antibodies (II-50/3: p=0,02, unpaired t-test and VIII-16: 
p=0,02, unpaired t-test). In addition the difference in endosialin expression between 
MSI and hereditary nonpolyposis colorectal cancer (HNPCC) was statistically signifi-
cant (p=0,04, unpaired t-test) with antibody II-50/3. 
 
Both endosialin antibodies showed the most intense immunostaining reaction in colo-
rectal cancers that are grade 2 (figure 12). In the colorectal cancer material there were 
grade 2 cases from every colorectal cancer group MSS, MSI and HNPCC. However no 
statistically significant difference (p>0,05, one-way analysis of variance) was found in 
the endosialin immunostaining reactions between different tumor grades. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 12. Immunostaining reactivity in different tumor grades of colorectal cancers. 
A. Stained with antibody II-50/3 and B. Stained with antibody VIII-16.  
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FIGURE 13. Endosialin in colorectal cancers, stained with endosialin antibody II-50/3. 
A. and B. Normal colon, C. Smooth muscle, D. Microsatellite instable, E. Microsatellite 
stable, F. Hereditary nonpolyposis colorectal cancer and G. Gastrointestinal stromal 
tumor. Arrows represent surface epithelial cells.  
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FIGURE 14. Endosialin in colorectal cancers, stained with endosialin antibody VIII-16. 
A. and B. Normal colon, C. Smooth muscle, D. Microsatellite instable, E. Microsatellite 
stable, F. Hereditary nonpolyposis colorectal cancer and G. Gastrointestinal stromal 
tumor. Arrows represent surface epithelial cells.  
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5.2.3 Endosialin in pancreatic cancers 
 
Pancreatic specimens stained with endosialin antibodies behaved in an interesting way. 
Firstly, there was not a visible difference in staining intensity between normal pancrea-
tic tissue and cancerous pancreas stained with either of the antibodies as shown in fig-
ures 16A, C and E and 16B, D and F. Secondly, it was observed that pancreatic ducts 
stained very intensively in normal pancreas specimens with either of the endosialin an-
tibodies (figures 16A and B). The same phenomenon was seen with pancreatic cancer 
specimens (figures 16C and D). However the overall immunostaining intensity was not 
particularly strong in pancreas specimens.  
 
There were not statistically significant differences in immunostaining intensity between 
pancreatic cancers and pancreatic ducts, (p>0,05, unpaired t-test). Statistically the inten-
sity of staining in pancreatic cancers was more intense with antibody VIII-16 (figures 
15A and B). (II-50/3: 0,7 ± 0,2 (SEM) and VIII-16: 1,1 ± 0,2 (SEM), unpaired t-test). 
However the staining intensity of pancreatic ducts was more intense with antibody II-
50/3 (figures 15A and B). (II-50/3: 1,5 ± 0,5 (SEM) and VIII-16: 1,3 ± 0,3 (SEM), un-
paired t-test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 15. Immunostaining reactivity in pancreas specimens. A. Stained with antibo-
dy II-50/3 and B. Stained with antibody VIII-16. 
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FIGURE 16. Endosialin in pancreatic cancers, stained with endosialin antibodies II-50/3 
and VIII-16. A. Normal pancreas stained with II-50/3, B. Normal pancreas stained with 
VIII-16, C. Pancreatitis chronica stained with II-50/3, D. Pancreatitis chronica stained 
with VIII-16, E. Adenocarcinoma ductale stained with II-50/3 and F. Adenocarcinoma 
ductale stained with VIII-16. Arrows represents pancreatic ducts.   
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5.2.4 Endosialin in hepatobiliary lesions  
 
There was no detectable positivity in immunostaining reaction in liver specimens 
stained with either of the endosialin antibodies as shown in figures 17A and B. In addi-
tion, all hepatobiliary lesions as well as normal liver specimens proved to be negative 
with either of the endosialin antibodies (figures 17E and F and 17G and H). 
 
The sample material of liver included, besides normal and cancerous specimens, hepat-
ic-, cirrhotic- and fatty liver specimens (figures 17C and D). Data of hepatic- and cirr-
hotic specimens are not shown.  All of these specimens tested negative in immunostain-
ing with either of the endosialin antibodies. It can be stated that neither of antibodies 
functioned better in hepatobiliary lesions. In this situation statistical analysis of hepato-
biliary lesions would prove unnecessary. 
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FIGURE 17. A. Normal liver stained with II-50/3, B. Normal liver stained with VIII-16, 
C. Fatty liver stained with II-50/3, D. Fatty liver stained with VIII-16, E. Colangio car-
cinoma stained with II-50/3, F. Colangio carcinoma stained with VIII-16, G. Hepatocel-
lular carcinoma stained with II-50/3 and H. Hepatocellular carcinoma stained with VIII-
16. 
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5.2.5 Endosialin in skin tumors  
 
Immunostaining reaction was very intense in skin specimens. Positive reaction occurred 
in both epidermis and dermis of normal skin specimens. Epidermis showed very intense 
reaction and dermis medium strength reaction with either of the endosialin antibodies 
(figures 19A and B). Skin cancers also showed very intense positive reaction, although 
with antibody VIII-16 reaction seemed to be a bit stronger (figures 19C and D). It was 
observed that there was variation in staining intensity rather between antibodies than 
between normal skin and skin cancers (figures 18A and B). 
 
There were not statistically significant difference in immunostaining reactivity between 
normal skin and skin cancers, (p>0,05, unpaired t-test). As it was already observed the 
variation in immunostaining intensity occurred between antibodies. This can be proved 
statistically as well. With antibody II-50/3 staining intensity between normal skin and 
skin cancers was almost similar (1,9 ± 0,3 (SEM) and 2,0 ± 0,3 (SEM), unpaired t-test) 
(figure 18A). With antibody VIII-16 same phenomenon was seen between normal skin 
and skin cancers (2,9 ± 0,1 (SEM) and 2,8 ± 0,3 (SEM), unpaired t-test) (figure 18B).  
 
 
 
 
  
 
 
 
 
 
 
 
FIGURE 18. Immunostaining reactivity in normal skin and in skin cancers. A. Stained 
with antibody II-50/3 and B. Stained with antibody VIII-16.  
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FIGURE 19. Endosialin in skin stained with antibodies II-50/3 and VIII-16. A. Normal 
skin stained with II-50/3, B. Normal skin stained with VIII-16, C. Basocellular carci-
noma stained with II-50/3 and D. Basocellular carcinoma stained with VIII-16. In fig-
ures e represents epidermis and d represents dermis.  
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6 DISCUSSION 
 
 
The aim of this study was to investigate expression of endosialin in tumor specimens by 
immunohistochemistry. Thin tissue sections were produced from tissue blocks with mi-
crotome. Tissue specimens were immunostained with automatic staining device using a 
staining kit. Immunostaining was performed according to the manufacturer’s protocol 
using indirect immunostaining technique. The secondary antibody labeled with HRP-
enzyme label was able to recognize endosialin found in tissue specimens. The formed 
enzyme reaction was visible for naked eyes and thus suitable for light microscopic ex-
amination. Intensity of immunostaining reaction was studied and results were analyzed 
statistically.  
 
It was found that both of the novel endosialin monoclonal antibodies II-50/3 and VIII-
16 functioned well in immunostaining. The used staining protocol appeared to be suita-
ble for detection of endosialin. In addition, dilutions under both endosialin monoclonal 
antibodies were found to be adequate, because there was not considerable variation in 
staining intensity between antibodies. Automatic staining decreases the possibility of 
faults that might happen in manual staining. 
 
However it was observed that the overall staining intensity was slightly more intense 
with endosialin monoclonal antibody VIII-16 compared to the antibody II-50/3. This 
phenomenon is seen in normal tissues as well as in cancerous specimens with the excep-
tion of normal colon specimens. In normal colon specimens the staining intensity with 
the antibody II-50/3 proved to be bit more intense compared to the staining intensity 
with the antibody VIII-16. 
 
It became evident that staining intensity was generally lower in normal tissues com-
pared to cancerous tissues stained with either of the endosialin antibodies. This result 
was the most clearly visible in nervous tissues of the brain specimens where brain tu-
mors showed clearly stronger intensity than normal nervous tissue of brain specimens. 
This was an expected result and confirms the theory that endosialin is expressed more 
intensively in cancerous tissues than in normal tissues. 
 
49 
 
There were differences in staining intensity between tissue types. Generally staining 
intensity was more intense in brain-, colon- and skin tumors compared to pancreatic 
cancers and hepatobiliary lesions. In pancreatic specimens the pancreatic ducts were 
observed to stain more intensively than normal pancreas or pancreatic cancer speci-
mens. In addition, every liver specimen proved to be negative despite the fact that the 
sample material contained besides normal and cancerous tissues also cirrhotic- and fatty 
liver specimens.  
 
There was a lot of variation in staining intensity in colon specimens. There were colo-
rectal cancers that stained on the other hand very intensively with either of the endosia-
lin antibodies, but elsewhere the staining intensity was nearly negative. Same phenome-
non was seen as well in normal colon specimens. In conclusion any specificity to ex-
pression of endosialin in colorectal cancers was not found compared to normal colon 
specimens. 
 
After all, the most intense staining was detected in skin specimens stained with the en-
dosialin antibody VIII-16. However it was found that normal skin specimens stained 
more intensively than skin cancer specimens (2,9 ± 0,1 (SEM) and 2,8 ± 0,3 (SEM), 
unpaired t-test). The gained staining result is contrary to expected result. It became evi-
dent, that expression of endosialin in skin specimens showed not specificity to cancers. 
 
On the contrary to skin specimens the expression of endosialin in brain tumors showed 
some specificity to cancerous tissues. Intense staining reactivity was not found in nor-
mal brain tissues, but both nervous tissues and blood vessels of brain tumors stained 
intensively. The most intense staining reactivity in brain tumors was seen in blood ves-
sels stained with endosialin antibody VIII-16. The mean intensity varied between 1,9 ± 
0,2 (SEM) – 2,3 ± 0,3 (SEM) unpaired t-test).  
 
Regardless of the good staining results statistic correlation between staining intensity 
and the tumor grade was not found either in brain tumors or in colorectal cancer speci-
mens. The results of this study did not clearly indicate whether endosialin could func-
tion as a specific molecular biomarker. In other words according to this study it cannot 
be confirmed that increased concentration levels of endosialin indicate cancer. However 
according to the results of this study it appears that the most potential targets for future 
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research of endosialin are brain tumors. Brain tumor research may have potential to-
wards the development to specify the main function of endosialin. 
 
There are various studies in which expression of endosialin has been studied by immu-
nohistochemistry. The expression of endosialin has been demonstrated in lots of human 
tumor tissue types in different studies. There are results that show similarity to the re-
sults of this study. In the immunohistochemical study of human brain tumors there were 
expression of endosialin in brain tumor specimens. Normal brain tissues were negative 
and did not express endosialin (Brady et al. 2004, 1274, 1283). Similar results were re-
ported with immunostained human colon carcinoma biopsies (Bagley et al. 2008, 187). 
 
Normal tissues have been immunostained in a study of mouse endosialin expression. 
Endosialin was observed to be expressed during the whole embryonic stage, but not in 
newborns or adult mice. (Rupp et al. 2006, 1, 4.) According to the results of this study, 
it was found that normal tissues, especially skin- and colon tissues, expressed endosia-
lin. There is no previous study demonstrating expression of endosialin in normal human 
tissues.  
 
When it comes to ethics, this study can be considered ethical. The sample material for 
this study was gained from hospitals. All tumor specimens used in this study were ob-
tained by surgeons from patients that were having symptoms because of some disease. 
Secondly, all of the specimens were removed in surgical procedure in order to find out 
histopathology of the disease and to understand the physiology of the disease. Through 
understanding of the histopathology and physiology of the disease it was possible to 
give patients the best treatment.  
 
In this study, lots of information about the expression of endosialin was produced. The 
expression was studied in several types of tissues and in both normal and cancerous 
tissues. In consequence this study offers wide-ranging point of view. The results of this 
study can be considered reliable, because staining intensities were quite comparable 
between each tumor types and because in statistical analysis standard errors of means 
were quite small. Endosialin may play a part in future cancer research and in develop-
ment of targeted cancer drugs.  
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In future it would be interesting to investigate the expression of endosialin with two 
different methods to see if the results show any similarity to the results of this study. 
The difference could be for example between labels. One of the labels could be an en-
zyme and the other a fluorescent. On the other hand it would be also worth trying to 
study expression of endosialin for example with RT-PCR to identify RNA-transcripts. 
The study of RNA-transcripts would bring some extra value for this study.  
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APPENDICES 
 
APPENDIX 1 
 
INDIRECT IMMUNOSTAINING METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Antibody labeling and indirect immunostaining method. A. Antibodies are 
labeled with HRP-enzyme label. B. Illustration of indirect immunostaining method. 
(Modified from Alberts et al. 2009, 145)  
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APPENDIX 2 
SUMMARY OF STAINED TISSUE SPECIMENS 
 
TABLE 1. Summary of stained tissue specimens divided into categories according to 
tissue types and staining with different endosialin antibodies. Category others contains 
specimens from duodenum, esophagus, antrum, corpus, colon and rectum. 
 
Tissue type n (II-50/3) n (VIII-16) 
Brain: 
Normal brain: 
Nervous tissue 7 7 
Blood vessels 7 7 
Brain tumors: 
Nervous tissue 106 106 
Blood vessels 106 106 
Colon: 
Normal colon 44 44 
Colorectal cancers 66 66 
Pancreas: 
Normal pancreas 2 3 
Pancreatic cancers 19 20 
Liver: 
Normal liver 3 3 
Hepatobiliary lesions 6 6 
Others (fatty liver, cirrhosis and hepatitis) 9 9 
Skin: 
Normal skin 6 6 
Skin cancers 8 8 
Other tissues: 
Normal tissues 20 20 
Cancerous tissues 4 4 
Total of normal tissue specimens: 197 198 
Total of cancerous tissue specimens: 216 217 
Total: 413 415 
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APPENDIX 3 
IMMUNOSTAINING PROGRAM AND REAGENT LAYOUT MAP 
FIGURE 2. Immunostaining program. This staining program is an example of program 
which is suitable for HRP-labeled indirect immunostaining. The primary antibody is the 
only variable in the program. Grey drops represent buffer rinse and white drops distilled 
water rinse. Incubation time is shown after each reagent.  
(continues) 
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APPENDIX 3:2 (2) 
 
 
FIGURE 3. Reagent layout map for immunostaining. The reagent layout map is based 
on the staining program. It represents the autostainer tube rack and reports for the vo-
lumes of reagents needed in immunostaining. Reagent volumes vary according to the 
number of slides to be stained.  
 
